MovDisordV3, PascalFrancis, Curation, bibRecord, 000209

Response to levodopa challenge in Tourette syndrome

Identifieur interne : 000209 ( PascalFrancis/Curation ); précédent : 000208; suivant : 000210

Response to levodopa challenge in Tourette syndrome

Auteurs : Kevin J. Black [États-Unis] ; Jonathan W. Mink [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2000.

RBID : Pascal:01-0016456

Descripteurs français

Pascal (Inist)
- Gilles de la Tourette syndrome, Lévodopa, Epreuve pharmacologique, Dose unique, Chimiothérapie, Traitement, Etude cas, Adulte.
Wicri :
- topic : Adulte.

English descriptors

KwdEn :
- Adult, Case study, Chemotherapy, Gilles de la Tourette syndrome, Levodopa, Pharmacologic test, Single dose, Treatment.

Abstract

A dopaminergic excess has been commonly postulated in the pathophysiology of tics, and an early report described acute worsening of tics with levodopa. However, dopamine agonists sometimes improve tics. We undertook this pilot study to determine whether people with tics could tolerate an acute dose of levodopa. Six adults with Tourette syndrome (TS) who had never been treated with neuroleptics took 150 mg levodopa by mouth under single-blind conditions after carbidopa pretreatment. All six subjects reported a decrease in self-rated tic severity (mean -40%, p <0.05), and three spontaneously asked if they could be prescribed levodopa for chronic treatment. Blinded videotape ratings of motor tic severity improved by 37% (p <0.02). A large, placebo-controlled trial will be required to confirm these findings, which raise important questions concerning the relationship of tic expression to dopaminergic activity.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 15`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Response to levodopa challenge in Tourette syndrome`
A11	`01`	`1`		`@1 BLACK (Kevin J.)`
A11	`02`	`1`		`@1 MINK (Jonathan W.)`
A14	`01`			`@1 Department of Psychiatry, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology @2 St. Louis, Missouri @3 USA @Z 1 aut.`
A14	`02`			`@1 Department of Neurology and Neurological Surgery, Washington University School of Medicine @2 St. Louis, Missouri @3 USA @Z 1 aut. @Z 2 aut.`
A14	`03`			`@1 Department of Radiology, Washington University School of Medicine @2 St. Louis, Missouri @3 USA @Z 1 aut.`
A14	`04`			`@1 Mallinckrodt Institute of Radiology @2 St. Louis, Missouri @3 USA @Z 1 aut.`
A14	`05`			`@1 Department of Anatomy and NeurobiologyandPediatrics, Washington University School of Medicine @2 St. Louis, Missouri @3 USA @Z 2 aut.`
A20				`@1 1194-1198`
A21				`@1 2000`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000092814950190`
A44				`@0 0000 @1 © 2001 INIST-CNRS. All rights reserved.`
A45				`@0 21 ref.`
A47	`01`	`1`		`@0 01-0016456`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 A dopaminergic excess has been commonly postulated in the pathophysiology of tics, and an early report described acute worsening of tics with levodopa. However, dopamine agonists sometimes improve tics. We undertook this pilot study to determine whether people with tics could tolerate an acute dose of levodopa. Six adults with Tourette syndrome (TS) who had never been treated with neuroleptics took 150 mg levodopa by mouth under single-blind conditions after carbidopa pretreatment. All six subjects reported a decrease in self-rated tic severity (mean -40%, p <0.05), and three spontaneously asked if they could be prescribed levodopa for chronic treatment. Blinded videotape ratings of motor tic severity improved by 37% (p <0.02). A large, placebo-controlled trial will be required to confirm these findings, which raise important questions concerning the relationship of tic expression to dopaminergic activity.
C02	`01`	`X`		`@0 002B02B11`
C03	`01`	`X`	`FRE`	`@0 Gilles de la Tourette syndrome @5 01`
C03	`01`	`X`	`ENG`	`@0 Gilles de la Tourette syndrome @5 01`
C03	`01`	`X`	`SPA`	`@0 Gilles de la Tourette síndrome @5 01`
C03	`02`	`X`	`FRE`	`@0 Lévodopa @5 04`
C03	`02`	`X`	`ENG`	`@0 Levodopa @5 04`
C03	`02`	`X`	`SPA`	`@0 Levodopa @5 04`
C03	`03`	`X`	`FRE`	`@0 Epreuve pharmacologique @5 05`
C03	`03`	`X`	`ENG`	`@0 Pharmacologic test @5 05`
C03	`03`	`X`	`SPA`	`@0 Prueba farmacológica @5 05`
C03	`04`	`X`	`FRE`	`@0 Dose unique @5 06`
C03	`04`	`X`	`ENG`	`@0 Single dose @5 06`
C03	`04`	`X`	`SPA`	`@0 Dosis única @5 06`
C03	`05`	`X`	`FRE`	`@0 Chimiothérapie @5 07`
C03	`05`	`X`	`ENG`	`@0 Chemotherapy @5 07`
C03	`05`	`X`	`SPA`	`@0 Quimioterapia @5 07`
C03	`06`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`06`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`06`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`07`	`X`	`FRE`	`@0 Etude cas @5 18`
C03	`07`	`X`	`ENG`	`@0 Case study @5 18`
C03	`07`	`X`	`SPA`	`@0 Estudio caso @5 18`
C03	`08`	`X`	`FRE`	`@0 Adulte @5 20`
C03	`08`	`X`	`ENG`	`@0 Adult @5 20`
C03	`08`	`X`	`SPA`	`@0 Adulto @5 20`
C07	`01`	`X`	`FRE`	`@0 Homme`
C07	`01`	`X`	`ENG`	`@0 Human`
C07	`01`	`X`	`SPA`	`@0 Hombre`
C07	`02`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`03`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`03`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`03`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`04`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 40`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 40`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 40`
N21				`@1 008`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002B12

Links to Exploration step

Pascal:01-0016456

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Response to levodopa challenge in Tourette syndrome</title>
<author><name sortKey="Black, Kevin J" sort="Black, Kevin J" uniqKey="Black K" first="Kevin J." last="Black">Kevin J. Black</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Psychiatry, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology and Neurological Surgery, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Radiology, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Mallinckrodt Institute of Radiology</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mink, Jonathan W" sort="Mink, Jonathan W" uniqKey="Mink J" first="Jonathan W." last="Mink">Jonathan W. Mink</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology and Neurological Surgery, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Anatomy and NeurobiologyandPediatrics, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">01-0016456</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 01-0016456 INIST</idno>
<idno type="RBID">Pascal:01-0016456</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002B12</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000209</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Response to levodopa challenge in Tourette syndrome</title>
<author><name sortKey="Black, Kevin J" sort="Black, Kevin J" uniqKey="Black K" first="Kevin J." last="Black">Kevin J. Black</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Psychiatry, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology and Neurological Surgery, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Radiology, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Mallinckrodt Institute of Radiology</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mink, Jonathan W" sort="Mink, Jonathan W" uniqKey="Mink J" first="Jonathan W." last="Mink">Jonathan W. Mink</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology and Neurological Surgery, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Anatomy and NeurobiologyandPediatrics, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Case study</term>
<term>Chemotherapy</term>
<term>Gilles de la Tourette syndrome</term>
<term>Levodopa</term>
<term>Pharmacologic test</term>
<term>Single dose</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Gilles de la Tourette syndrome</term>
<term>Lévodopa</term>
<term>Epreuve pharmacologique</term>
<term>Dose unique</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Etude cas</term>
<term>Adulte</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Adulte</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A dopaminergic excess has been commonly postulated in the pathophysiology of tics, and an early report described acute worsening of tics with levodopa. However, dopamine agonists sometimes improve tics. We undertook this pilot study to determine whether people with tics could tolerate an acute dose of levodopa. Six adults with Tourette syndrome (TS) who had never been treated with neuroleptics took 150 mg levodopa by mouth under single-blind conditions after carbidopa pretreatment. All six subjects reported a decrease in self-rated tic severity (mean -40%, p <0.05), and three spontaneously asked if they could be prescribed levodopa for chronic treatment. Blinded videotape ratings of motor tic severity improved by 37% (p <0.02). A large, placebo-controlled trial will be required to confirm these findings, which raise important questions concerning the relationship of tic expression to dopaminergic activity.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>15</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Response to levodopa challenge in Tourette syndrome</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BLACK (Kevin J.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MINK (Jonathan W.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Psychiatry, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology and Neurological Surgery, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Radiology, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Mallinckrodt Institute of Radiology</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Anatomy and NeurobiologyandPediatrics, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>1194-1198</s1>
</fA20>
<fA21><s1>2000</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000092814950190</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2001 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>21 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>01-0016456</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>A dopaminergic excess has been commonly postulated in the pathophysiology of tics, and an early report described acute worsening of tics with levodopa. However, dopamine agonists sometimes improve tics. We undertook this pilot study to determine whether people with tics could tolerate an acute dose of levodopa. Six adults with Tourette syndrome (TS) who had never been treated with neuroleptics took 150 mg levodopa by mouth under single-blind conditions after carbidopa pretreatment. All six subjects reported a decrease in self-rated tic severity (mean -40%, p <0.05), and three spontaneously asked if they could be prescribed levodopa for chronic treatment. Blinded videotape ratings of motor tic severity improved by 37% (p <0.02). A large, placebo-controlled trial will be required to confirm these findings, which raise important questions concerning the relationship of tic expression to dopaminergic activity.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B11</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Gilles de la Tourette syndrome</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Gilles de la Tourette syndrome</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Gilles de la Tourette síndrome</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Epreuve pharmacologique</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Pharmacologic test</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Prueba farmacológica</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dose unique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Single dose</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Dosis única</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Etude cas</s0>
<s5>18</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Case study</s0>
<s5>18</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Estudio caso</s0>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Adulte</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Adult</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Adulto</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>40</s5>
</fC07>
<fN21><s1>008</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000209 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000209 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:01-0016456
   |texte=   Response to levodopa challenge in Tourette syndrome
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Response to levodopa challenge in Tourette syndrome

Response to levodopa challenge in Tourette syndrome

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri